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INTRODUCTION
Regardless of adjuvant treatment, cytokeratin-positive
cells found in the bone marrow of patients with stages I, II,
or III breast cancer at diagnosis appear to be capable of
causing systemic disease relapse and are an independent
prognostic indicator of risk of death from cancer [1-3]. Sim-
ilarly, in patients with advanced breast cancer treated with
high-dose chemotherapy, tumor cell contamination of the
Breast Cancer Cell Contamination of Blood Stem Cell
Products in Patients with Metastatic Breast Cancer:
Predictors and Clinical Relevance
Andrew L. Pecora,1 Hillard M. Lazarus,2 Andrew A. Jennis,1 Robert A. Preti,3 Stuart L. Goldberg,1
Scott D. Rowley,1 Susan Cantwell,1 Brenda W. Cooper,2 Edward A. Copelan,4 Roger H. Herzig,5
Richard Meagher,6 M. John Kennedy,7 Luke P. Akard,8 Jan Jansen,8 Amy Ross,9 Marina Prilutskaya,10
John Glassco,10 Douglas Kahn,10 Thomas J. Moss10
1Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey; 2Ireland Cancer Center, Cleveland,
Ohio; 3Progenitor Cell Therapy, LLC, Saddle Brook, New Jersey; 4Department of Medicine, Ohio State University,
Columbus, Ohio; 5James Graham Brown Cancer Center, Louisville, Kentucky; 6Department of Medicine, Rush Presby-
terian St. Lukes Medical Center, Chicago, Illinois; 7St. James Hospital, Dublin, Ireland; 8St. Francis Cancer Center, 
Indianapolis, Indiana; 9Nexell Therapeutics, Inc, Irvine, California; 10BIS-Impath Laboratories, Reseda, California
Correspondence and reprint requests: Andrew L. Pecora, MD, FACP, Cancer Center Director, Hackensack 
University Medical Center, 20 Prospect Street, Hackensack, NJ 07601 (e-mail: apecora@humed.com).
Received November 8, 2001; accepted May 23, 2002
ABSTRACT
The incidence and clinical relevance of tumor cells contaminating the stem cell products of patients with advanced
breast cancer treated with high-dose chemotherapy is uncertain because prior studies used small sample sizes and
lacked standardization of the immunocytochemistry (ICC) detection method used. We evaluated blood stem cell
and bone marrow samples obtained from 535 women with metastatic breast cancer who received high-dose chemo-
therapy and unmanipulated mobilized blood stem cell support. Of the patients tested, 20.6% and 26.3% had blood
stem cell and bone marrow contamination, respectively. Blood stem cell contamination was significantly more fre-
quent in patients with marrow involvement than in patients without marrow involvement (35% versus 18.4%,
respectively; P = .009). In fact, according to multivariate analysis results, marrow involvement was the only signifi-
cant predictor for blood stem cell product contamination. Patients without marrow involvement who had fewer
apheresis procedures were also observed to have a significantly lower incidence rate of blood stem cell contamina-
tion than patients who had more procedures (P ≤ .008), and patients who received combined chemotherapy and
cytokine mobilization therapy had less contamination than patients who received cytokine alone (P = .0001). Com-
bined mobilization therapy appears to be associated with a lower incidence of contamination as a result of fewer
apheresis procedures rather than through an antitumor effect of chemotherapy (P ≤ .001). Patients with ICC-negative
blood stem cell products had significantly longer progression-free survival (PFS) and overall survival (OS) than did
patients with ICC-positive blood stem cell products (median PFS, 401 versus 291 days, respectively, P = .007;
median OS, 1060 versus 697 days, P = .009) . However, multivariate analysis did not reveal any significant indepen-
dent predictors of survival outcomes. Thus, further study is needed to determine if contaminating tumor cells in the
stem cell products of breast cancer patients ever directly impact survival outcomes or are only indicative of residual
in vivo disease in high-dose chemotherapy recipients.
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bone marrow harvest products detected by immunocyto-
chemistry (ICC) or polymerase chain reaction is associated
with shorter periods of disease-free survival (DFS) and
lower rates of overall survival (OS) [4-6]. In addition, several
investigators have shown that malignant cells also contami-
nate blood stem products, and results of gene-marking stud-
ies indicate that these cells contribute to disease relapse after
autologous transplantation performed for treatment of
leukemia and neuroblastoma [7-9].
However, in several small series involving fewer than
90 patients with advanced breast cancer treated with high-
dose chemotherapy, DFS and OS rates were similar regard-
less of the ICC status of the infused blood stem cell product
[10-12]. The small sample size of these studies, a lack of
standardization and sensitivity of the ICC detection method
used, and selection of patients with advanced and in some
cases refractory disease may explain the lack of an association
between ICC status and high-dose chemotherapy treatment
outcomes [13-15]. Thus, it remains unknown if relapse
observed in patients with advanced breast cancer, including
those who achieve a complete response (CR) after treatment
with high-dose chemotherapy, is due solely to growth of in
vivo residual disease or is also a consequence of breast cancer
cells infused after high-dose chemotherapy [16-18].
We report results of an ICC analysis on blood stem cell
and bone marrow samples obtained from 535 women with
metastatic breast cancer who received high-dose chemo-
therapy and unmanipulated mobilized blood stem cell sup-
port. We evaluated the factors that affected blood stem cell
product contamination and the relationship between prod-
uct contamination and DFS and OS.
PATIENTS AND METHODS
Patient Selection
Between July 1990 and November 1997, specimens
were taken from 535 women with metastatic breast cancer
who underwent 1551 blood stem cell collections and subse-
quently were treated with high-dose chemotherapy and
blood stem cell support. During the study period, all
patients at each participating institution were included.
Breast cancer diagnosis and staging were performed using
standard histopathologic and radiologic techniques. All
patients received standard conventional-dose chemotherapy
prior to initiation of mobilization therapy. Patients were
required to have an Eastern Cooperative Oncology Group
performance status score of 0 to 2 and adequate pulmonary,
cardiac, hepatic, and renal function. All patients were
human immunodeficiency virus seronegative and provided
written consent approved by the treatment center institu-
tional review boards.
Blood Stem Cell Collection
Blood stem cell collections were performed according to
institutional protocols and target CD34+ stem cell dose
using the Fenwal CS 3000 (Baxter, Deerfield, IL) or the
Coulter Spectra (Cobe BCT, Lakewood, CO) instrument
after mobilization with commercially available hemato-
poietic growth factors (cytokine) alone or in combination
with chemotherapy. There were no predetermined clinical
criteria used to select mobilization regimens.
Preparation of Marrow and Blood Stem Cell
Specimens
Approximately 3 to 5 mL of bone marrow and 1 to 3 mL
of blood stem cell products were shipped to Impath/Bis lab-
oratories (Reseda, CA) from participating centers. Bone
marrow samples were obtained prior to mobilization ther-
apy. All samples were processed within 48 hours of collec-
tion. Samples were diluted in Liebowitz L-15 medium
(Gibco/BRL, Grand Island, NY) supplemented with 10%
fetal bovine serum. Diluted samples were layered over
Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) and then
subjected to density-gradient centrifugation. The mononu-
clear cell fraction was tested for viability using a trypan blue
exclusion assay and then cytocentrifuged onto slides and
stored at 4°C for future immunostaining.
Immunostaining
ICC procedures have been described previously [5,19].
Brieﬂy, within 24 hours, cytopreparations were ﬁxed in (2:1)
paraformaldehyde/methanol ﬁxative, washed thoroughly in
Dulbecco’s modified phosphate buffered saline (PBS)
(Gibco/BRL), and placed on an automated immunostainer
(TechMate; Ventana, Tucson, AZ). Alkaline phosphatase
(AP) immunostaining was then performed. Slides were incu-
bated in the following order: antibreast monoclonal anti-
body cocktail (CK8/CK18; 1:200; Caltag Burlingame, CA,
and TFS-2; 1:2000; Biodesign, Saco, ME), blocking solu-
tion, secondary antibody, AP complex, chromogen, and
ﬁnally hematoxylin. Buffer washes were performed between
each step. Slides were reviewed under the microscope and
results were considered positive when immunostaining was
observed on at least 75% of the cell membrane and cyto-
plasm and the morphology was consistent with a malignant
cell. A total of up to 5 × 105 cells were directly examined per
specimen. Two or more independent observers confirmed
the immunostaining results. Positive control slides consisted
of cultured breast cancer cells (CAMA-1; generously pro-
vided by Dr. Adrian Gee, Baylor University, Texas) seeded
into normal marrow or blood stem cell products at a dilu-
tion of at least 1 tumor cell per 5.0 × 105 hematopoietic cells
and immunostained as described above. Negative control
slides were prepared from patient samples using mouse
serum without anti–breast cancer antibodies. This assay pre-
viously has been shown to be sensitive enough to detect
1.0 breast cancer cells per million hematopoietic cells
reviewed and is nonreactive with hematpoietic cells [19,20].
Response Assessment
Response to therapy was assessed using standard imag-
ing techniques (total body computed tomographic scan,
bone marrow aspiration, bone surveys, and bone scans).
Response deﬁnitions included CR, which was deﬁned as res-
olution of disease sites, including recalcification of lytic
bone lesions and normalization of bone scan in patients with
bone-only disease or complete resolution of soft tissue dis-
ease and evidence of bone healing, regardless of bone scan
results, in patients with combined bone and soft tissue dis-
ease. Partial response (PR) was deﬁned as ≥50% but <100%
reduction in bidimensional measurable disease or, in bone-
only disease, x-ray results showing healing lesions and bone
scan results showing static lesions for 8 or more weeks.
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Posttreatment Follow-up
Participating centers performed restaging evaluations
according to their routine practice during and after comple-
tion of all chemotherapy treatment. Minimum follow-up
was performed every 3 months in year 1, every 6 months in
years 2 through 5, and then yearly thereafter.
Statistical Analysis
Patient samples with any blood stem cell product con-
taining cells stained by immunocytochemistry were desig-
nated as ICC positive. Patients were grouped according to
the mobilization regimen they received and the number of
apheresis procedures performed, and the Fisher exact test was
used to compare patient characteristics, including age, num-
ber and sites of disease, number of chemotherapy regimens
administered before high-dose therapy, and estrogen receptor
status, between these groups. Patients were also grouped
according to the presence of marrow involvement, mobiliza-
tion regimen used, number of apheresis procedures, and clini-
cal status at the time of apheresis collection, and in univariate
analysis a chi-square test was performed to detect differences
in the incidence of tumor cell contamination between these
groups. Multivariate analysis was used to determine and
adjust for signiﬁcant predictors of blood stem cell product
contamination using logistic regression. Marrow involvement
and clinical status at the time of apheresis collection, the
number of apheresis procedures, and the mobilization regi-
men used were considered with a backward elimination pro-
cedure used to remove nonsigniﬁcant variables. DFS and OS
were calculated from the time of blood stem cell product
infusion. Kaplan-Meier curves with equality testing using log-
rank statistics and Cox proportional hazards regression model
were used to determine the relationship between blood stem
cell product contamination and mobilization regimen used,
clinical status, bone marrow contamination, blood stem cell
product contamination, number of apheresis procedures per-
formed, and progression-free survival (PFS) and OS.
RESULTS
Incidence of Contamination
Overall. Blood stem cell products from 110 (20.6%) of the
535 patients sampled contained breast cancer cells, according
to ICC analysis results. Paired marrow samples obtained
within 60 days prior to apheresis collection were available
from 228 patients. ICC analysis results revealed bone marrow
involvement in 60 (26.3%) of the 228 patients tested.
Association between Marrow and Blood Stem Cell Contami-
nation. Of the 60 patients with marrow involvement, 21
(35%) had blood stem cell contamination. In comparison,
blood stem cell contamination was observed in signiﬁcantly
fewer patients without marrow involvement (31/168, 18.4%,
P = .009).
Association between the Mobilization Regimen and Blood
Stem Cell Contamination. Mobilization regimens were avail-
able to 477 of the 535 patients (Table 1). Overall, blood stem
cell contamination was more frequent (49 of 190, 25.8%) in
patients who received cytokine mobilization alone than in
patients who received combined chemotherapy and cytokine
therapy (44 of 287, 15.3%, P = .005). Mobilization data avail-
able from 149 of the patients without marrow involvement
revealed a signiﬁcantly higher incidence of blood stem cell
contamination in those receiving cytokine mobilization ther-
apy than in those receiving combined chemotherapy
(cytokine, 22 of 63 [35%] versus combined, 8 of 86 [9.0%];
P = .0001). There was no difference in the incidence of tumor
cell contamination between patients who received granulo-
cyte colony-stimulating factor (G-CSF)-mobilized versus
those who received granulocyte-macrophage CSF–mobilized
blood stem cell products (27% versus 22.4%). Nor was there
any difference in contamination incidence between patients
who received products mobilized by cytokine and those who
received single or multiagent chemotherapy. In contrast,
among 55 patients with marrow involvement, the incidence
of blood stem cell involvement was similarly high, regardless
of the mobilization regimen used (cytokine alone, 9 of 30
[30%]; combined, 11 of 25 [44%]; P = .28) (Table 2).
Number of Apheresis Collections and Incidence of Contamina-
tion. Apheresis collection data were available from 476 of the
535 patients analyzed. The incidence of blood stem cell
product contamination increased as the number of apheresis
collections increased (Table 3). Patients requiring 1 apheresis
collection had a signiﬁcantly lower incidence of blood stem
cell product contamination (8 of 149, 5.3%) than patients
requiring 2 (15 of 97, 15.5%), 3 (28 of 92, 30.4%), 4 (16 of
52, 30.7%) or more (29 of 60, 48.3%) collections (P ≤ .008).
Similarly, the incidence of blood stem cell product contami-
nation in patients requiring 2 collections was significantly
lower than in those patients requiring more than 2 collec-
tions (P = .004). Patients requiring 3 or more collections had
a similar incidence of contamination.
The relationship between the number of apheresis proce-
dures and the incidence of blood stem cell contamination,
however, could have resulted from an increase in the sam-
pling of patients requiring multiple aphereses. To address this
possibility, we performed triplicate ICC analysis on apheresis
samples chosen randomly from 53 of the 149 patients who
required 1 apheresis collection, and the results were com-
pared to those from 58 patients requiring 3 apheresis collec-
tions. Patients requiring 1 apheresis procedure were again
Table 1. Patient Characteristics
ICC ICC
Negative Positive
Age, median (range), y 45 (25-63) 44 (32-61)
Mobilization regimen
Cytokine
G-CSF 108 40
GM-CSF 33 9
Chemotherapy/cytokine
Single agent/G-CSF 107 19
Multiagent/G-CSF 136 25
Clinical status at time of harvest
CR 64 10 
PR 160 51 
High-dose chemotherapy
Cyclophosphamide, thiotepa, novantrone 85 34 
Cyclophosphamide, thiotepa 40 13
Cyclophosphamide, thiotepa, carboplatin 118 30 
Busulfan, melphalan, thiotepa 52 14
Carmustine, platinol, cyclophosphamide 89 24 
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found to have a signiﬁcantly lower incidence of blood stem
cell product contamination (6 of 53 [11.3%] versus 19 of
58 [32.7%]; P = .007). In contrast, the incidence of blood
stem cell product contamination using triplicate sampling
done on the ﬁrst apheresis product from patients requiring
3 apheresis procedures was similar (9 of 58, 15.5%) to the
observed incidence in the 1 apheresis–collection group sam-
pled in triplicate (11.3%, P = .52).
The mobilization regimen had no effect on the incidence
of blood stem cell product contamination when assessed
according to the number of apheresis collections. Patients
requiring 1 apheresis collection had a similarly low incidence
of contamination regardless of whether cytokine (2 of 42,
5.8%) or combined (3 of 80, 3.8%) mobilization therapy was
used (P = .83). The same was true in patients requiring
2 apheresis procedures (cytokine, 25% versus combined
mobilization therapy, 10.6%; P = .17), 3 procedures (27.2%
versus 33.3%, P = .75), and greater than 4 procedures (43.3%
versus 36.5%, P = .59). The number of days from the last
treatment with chemotherapy and the number of apheresis
collections performed were analyzed in 224 of 447 patients
with known mobilization regimens. Sixty-eight patients
mobilized with cytokine were compared to 156 patients who
received combined therapy.
The number of days from last chemotherapy was signiﬁ-
cantly greater in patients given cytokine (median, 34 days;
mean, 42.3 days) than in patients mobilized with combined
therapy (median, 11 days; mean, 12.9 days) (P < .001). Simi-
larly, the number of apheresis procedures was greater in
patients treated with cytokine (median, 3 days; mean 3.31 days)
than in the patient group mobilized with chemotherapy and
cytokine (median, 2 days; mean, 2.58 days) (P ≤ .001).
Disease Status at Collection. Data were available for analy-
sis regarding the disease status at the time of apheresis
collection of a group of 285 patients who had achieved a
complete or partial clinical remission. Patients in complete
remission had a lower incidence of blood stem cell product
contamination (10 of 74, 13.5%) than did patients in partial
remission (51 of 211, 24.2%), but the difference was not sta-
tistically signiﬁcant. The incidence of blood stem cell prod-
uct contamination in the CR group did not differ according
to the mobilization regimen used (cytokine, 5 of 34, 14.7%
versus combined, 5 of 40, 12.5%). On the other hand,
patients in partial remission given combined mobilization
therapy had a significantly lower contamination incidence
(24 of 126, 19.0%) than did those who received cytokine
mobilization (27 of 85, 31.7%) (P = .05).
Clinical Outcomes
Patients with ICC-negative bone marrow had a signiﬁ-
cantly longer PFS (median, 458 days) than did patients with
ICC-positive bone marrow (median, 146 days; P = .0001).
Median PFS was longer in the group of 168 patients whose
bone marrow and blood stem cell products were both ICC
negative (471 days, P = .007). OS data from this subgroup of
patients were not available for analysis.
Clinical follow-up data for analysis were available from
403 of the 447 patients whose mobilization regimens were
known. PFS and OS rates were assessed in 125 patients
given cytokine and 191 patients given combined mobiliza-
tion therapy who had ICC-negative blood stem cell prod-
ucts. In addition, 46 patients who underwent mobilization
using cytokine and 41 patients given combined therapy who
had ICC-positive blood stem cell products were also
assessed. In total, patients with ICC-negative blood stem
cell products had longer PFS (median, 401 versus 291 days;
P = .007) and OS (median, 1060 versus 697 days; P = .009)
than patients with ICC-positive products.
Results of survival analysis according to the mobilization
regimen used (Table 4) showed that patients with ICC-
negative blood stem cell products given combined therapy
had longer PFS (P = .002) and OS (P = .001) than did
patients with ICC-positive products who underwent mobi-
lization with combined therapy. In contrast, mobilization
with cytokine was associated with similar PFS (P = .3) and
OS (P = .34), regardless of ICC status.
Response to chemotherapy correlated with blood stem
cell contamination and PFS and OS. Patients who achieved a
CR to chemotherapy prior to blood stem cell collection had
similar PFS regardless of blood stem cell product ICC status
(median, 418 days for ICC positive versus 512 days for ICC
negative; P = .61). In this group, at the time of the analysis,
median OS was not reached. In contrast, patients achieving a
PR prior to mobilization therapy had a signiﬁcantly longer
median PFS and OS if their blood stem cell products were
ICC negative (PFS, 344 days for ICC negative versus
243 days for ICC positive; P = .001) (OS, 979 days for ICC
negative versus 594 days for ICC positive; P = .001).
Table 2. Blood Stem Cell Product Contamination (N = 204)*
Bone Marrow Mobilization ICC+, n ICC–, n % Positive P
ICC– Cytokine alone 22 41 34.9
Combined 8 78 9.3 .0001
ICC+ Cytokine alone 9 21 30.0
Combined 11 14 44.0 .28
*Combined indicates cytokine and chemotherapy.
Table 3. Apheresis Contamination Rate
No. of Apheresis
Procedures ICC+ ICC– % Positive
1 8 141 5.3*
2 15 82 15.5†
3 28 64 30.4‡
4 16 36 30.7
>4 29 60 48.3
*1 < 2, 3, 4, and more than 4 apheresis (P ≤ .008).
†2 < 3, 4, and more than 4 apheresis (P = .004).
‡3, 4, and more than 4 apheresis (no difference).
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CR patients with ICC-positive products also had a
longer median PFS than did PR patients with ICC-positive
products (CR group, 418 days versus PR group, 243 days;
P = .01).
Multivariate Analysis
A logistic regression analysis revealed bone marrow
involvement to be the only signiﬁcant independent predictor
for blood stem cell contamination (P = .03) when this factor
was analyzed together with the number of apheresis proce-
dures (P = .07), clinical status at the time of transplantation
(P = .20), and the mobilization regimen used (P = .08). Blood
stem cell contamination for the marrow ICC-positive group
was 2.43 times greater than that of the marrow ICC-negative
group. Removal of bone marrow ICC status from the analy-
sis resulted in the number of apheresis procedures achieving
signiﬁcance as a predictor of blood stem cell contamination
(P < .001) independent of clinical status (P = .17) and the
mobilization regimen used (P = .54). In this analysis the odds
ratio of observing an ICC-positive blood stem cell product
increased by 2.13 for each additional apheresis procedure.
Factors including patient age, number of regimens
administered prior to transplantation, number and type of
disease sites, and estrogen receptor status were found to be
balanced between groups of patients divided by the type of
mobilization and the number of apheresis procedures
(Table 5). Clinical status, bone marrow contamination,
blood stem cell product contamination, mobilization regi-
men, and the number of apheresis procedures performed
were coanalyzed. There were no significant independent
predictors of DFS or OS.
DISCUSSION
In a heterogeneous group of 535 women with metastatic
breast cancer, the incidence rates of blood stem cell product
and bone marrow contamination were found to be 20.6% and
26.3%, respectively. These data are consistent with results
observed in other smaller studies [1,2,4-6,10,19,21-24]. A
more recent report of a study including 203 patients with
stages II through IV breast cancer, from 15 centers, revealed
a substantially lower incidence of marrow (8.3%) and blood
stem cell (4.5%) contamination despite the use of an ICC
technique of similar sensitivity (1.7 breast cancer cells per
million hematopoietic cells reviewed) to the one used in our
study [25]. In that study, the incidence of marrow and blood
stem cell product contamination was noted to be equally low
when compared between patients with stage II/III and IV
disease, suggesting that the reduced incidence of contamina-
tion observed in the advanced disease patients might be due
to selection of subjects with low-volume metastatic disease.
In fact, other investigators have found that patients with
ICC-positive products are more likely to have a greater
number of involved axillary nodes and more advanced
metastatic disease than are patients with ICC-negative
products [10].
In our analysis, marrow involvement as detected by ICC
was associated with a significantly higher incidence (odds
ratio, 2.43) of blood stem cell contamination. Moreover,
ICC marrow involvement was the only signiﬁcant predictor
for blood stem cell status at apheresis and mobilization regi-
men used. It should be noted, however, that 18.4% of sam-
pled patients with ICC-negative marrow had ICC-positive
blood stem cell products. Thus, our data indicate that it is
insufﬁcient to use the absence of marrow involvement as an
assurance that a tumor cell–free blood stem cell product will
be collected.
Our data clearly show that as the number of apheresis
procedures increases from 1 through 3 procedures, the inci-
dence of blood stem cell product contamination increases
signiﬁcantly. This effect appears not to be a result of sam-
pling frequency as suggested by others, because the inci-
dence of contamination remained signiﬁcantly lower in the
patient group requiring 1 apheresis procedure when sam-
pled in triplicate (11.3%) than in the patient group requir-
ing 3 apheresis procedures (32.7%, P = .007) [10]. Patient
characteristics (age, estrogen receptor status, number and
sites of disease, and prior chemotherapy regimens) were bal-
anced between groups divided by the number of apheresis
procedures performed. Moreover, there was no evidence
that the incidence of ICC contamination was greater on any
particular day of collection. Instead the incidence increased
as the number of apheresis procedures increased. These
observations are supported by those of Franklin and col-
leagues, who noted that blood contamination during
apheresis collections is intermittent and sporadic, further
refuting the notion that continued apheresis selectively
mobilizes tumor cells [25].
Data for evaluation were available from the majority of
patients regarding the type of mobilization regimen and
number of apheresis procedures performed. Overall,
Table 4. Effect of Mobilization Regimen on Clinical Outcomes
ICC No. of PFS, OS,
Mobilization Status Patients Median, d Median, d
Combined Negative 191 455 1054
Positive 41 243 525
Cytokine Negative 125 352 1060
Positive 46 295 985
Table 5. Balance of Predictive Variables
Mobilization No. of Aphereses
Predictive Variable Combined/Cytokine 1/2/>3
Age, median 45/44 years* 45/45/45 years*
Prior therapy
None 65%/61%* 65%/59%/60%*
One regimen 32%/35%* 30%/40%/31%*
≥2 regimens 3%/4%* 5%/1%/7%*
Disease sites
Marrow† 18%/20%* 23%/14%/17%*
Bone† 21%/21%* 21%/22%/21%*
Other† 4%/8%* 6%/3%/7%*
Liver 18%/14%* 14%/21%/15%*
≥2 Sites 39%/37%* 36%/40%/39%*
Estrogen receptor status
Positive 68%/68%* 70%/69%/66%*
Negative 32%/32%* 30%/30%/33%*
*Not signiﬁcant.
†Only site of disease.
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patients who received combined therapy as the mobilization
stimulus had a signiﬁcantly lower incidence of blood stem
cell contamination compared to patients given cytokine
alone (15.3% versus 25.8%, P = .005). Of note, this differ-
ence was observed only in patients with ICC-negative bone
marrow. Therefore, reducing the number of apheresis col-
lections by using combined therapy for mobilization, partic-
ularly in patients without marrow involvement, may reduce
the incidence of blood stem cell product contamination.
A subset analysis was performed to investigate the rela-
tionship between the types of mobilization regimen used, the
number of apheresis procedures performed, and the inci-
dence of blood stem cell product contamination. We noted
that there was a substantially greater number of days
(median, 34 days) between the last dose of chemotherapy and
the ﬁrst day of apheresis collection in the group receiving
cytokine alone compared to patients whose mobilization reg-
imen involved combined therapy (median, 11 days; P < .001).
During this delay, growth of malignant cells may have
occurred and may have been the reason for the higher inci-
dence of blood stem cell contamination in patients who had
ICC-negative marrow and received cytokine-alone mobiliza-
tion therapy . This explanation for the higher incidence of
blood stem cell contamination does not appear to be valid,
however, because the incidence of ICC-detected contamina-
tion is similar on the ﬁrst day (cytokine, 4.8% versus com-
bined, 3.8%) and each subsequent day of apheresis collection
regardless of the mobilization regimen used. In addition, the
median number of collections performed in the combined
therapy group (2) was lower than that in the cytokine group
(3). Other investigators also have observed the need for
fewer apheresis procedures when combined mobilization
therapy is used than when cytokine alone is used [26].
Therefore, a more likely explanation for the higher incidence
of blood stem cell product contamination in the cytokine-
alone mobilization group is the greater number of apheresis
procedures required. In patients with ICC-positive bone
marrow, the incidence of blood stem cell product contamina-
tion was equally high, regardless of the mobilization regimen
used. Further study is required to determine if this ﬁnding
results from the need for a greater number of apheresis pro-
cedures because marrow tumor involvement adversely affects
mobilization or from a higher day 1 contamination rate than
occurs in ICC-negative marrow patients.
The addition of chemotherapy to cytokine may particu-
larly benefit patients who are in a partial remission at the
time of apheresis collection. In this study, the incidence of
blood stem cell product contamination in these patients was
substantially lower (19.7%) than that in partial remission
patients given cytokine-alone mobilization (31.7%, P = .05).
This difference was not observed in patients achieving a
complete remission, suggesting that the extra day of aphere-
sis collection associated with the use of cytokine-alone
mobilization may not be signiﬁcant in this group of patients
with a lower tumor burden. Prospective study of cytokine
versus combined mobilization therapy in patients without
ICC marrow involvement is needed to definitively deter-
mine if the lower incidence of ICC blood involvement is
due to the cytotoxic effect of chemotherapy or, as reported
in other studies, simply due to a reduction in the number of
aphereses [10,27].
Clinical outcomes appeared to correlate with the status
of disease at the time of apheresis collection. Patients in a
CR had similar PFS regardless of blood stem cell product
ICC status. In contrast, patients in a PR with ICC-negative
products had significantly longer PFS and OS than did
those in a PR with ICC-positive products (P = .001). Some
but not all patients with ICC-positive blood stem cell prod-
ucts have breast cancer cells capable of growing in in vitro
clonogenic assays. Thus our data suggest that a difference
may exist in the viability of ICC-positive cells in patients in
complete versus partial remission at the time of mobilization
(T.J.M., A.L.P., H.M.L., et al., unpublished data).
Identification and removal of contaminating cancer
cells from blood and marrow stem cell products prior to use
has yet to be deﬁnitively shown to decrease the relapse rate
in patients with solid tumors treated with high-dose
chemotherapy [28-30]. Recent laboratory and clinical trials
have demonstrated more effective approaches in eliminat-
ing contaminating malignant cells from marrow and blood
stem cell products using chemical agents, monoclonal anti-
bodies, CD34+ afﬁnity devices, ex vivo expansion, and other
techniques [20,28-34]. Thus, the importance of blood stem
cell product contamination may increase with improve-
ments in eradication of in vivo residual disease in patients
with metastatic breast cancer treated with high-dose
chemotherapy [30].
Nonetheless, in our study multivariate analysis revealed
no significant independent predictor of PFS or OS.
Factor(s) such as in vivo chemotherapy-resistant minimal
residual disease appear to have more inﬂuence on these out-
comes than do clinical status, bone marrow or blood stem
cell product contamination, mobilization regimen, and the
number of apheresis procedures performed. Of note, breast
cancer cells capable of growth in a clonogenic soft agar
assay, when present in blood stem cell products, are associ-
ated with significantly reduced DFS and OS regardless of
the patient clinical status at the time of apheresis collection
(T.J.M., A.L.P., H.M.L., et al., unpublished data).
The utility of high-dose chemotherapy and blood stem
cell support in advanced breast cancer has not yet been
demonstrated [35-37]. However, several reports indicate
that patients with metastatic breast cancer who present with
limited disease and have a good response to induction
chemotherapy may experience improvements in PFS and
OS when treated with high-dose chemotherapy [29,38,39].
In our study, factors shown to be predictive of PFS in auto-
transplantation for metastatic breast cancer were balanced
between mobilization type and number of apheresis sub-
groups [38]. Collectively our data suggest that reducing the
number of apheresis procedures by using combined-therapy
mobilization may benefit some patients. Firm conclusions
from our data are limited, however, given the retrospective
analysis design of this study. In future trials, definitive
assessment of the effect on clinical outcomes of methods
aimed to reduce minimal residual disease, including limiting
the number of apheresis procedures, using CD34+ blood
stem cell selection, and administering tandem cycles of
high-dose chemotherapy, will require prospective study
[13,29,40-42]. In this setting, the study of nonchemotherapy
posttransplantation treatments including targeted immune
therapies may be most applicable [43-46].
A. L. Pecora et al.
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